A simplified strategy for donor-recipient size-matching in lung transplant for interstitial lung disease.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
11 2021
Historique:
received: 08 12 2020
revised: 16 06 2021
accepted: 22 06 2021
pubmed: 25 7 2021
medline: 4 3 2022
entrez: 24 7 2021
Statut: ppublish

Résumé

Donor-recipient size-matching has been repeatedly reported to improve outcomes following lung transplantation (LTx). However, there is significant variability in practice and the optimal strategy for size-matching is yet to be defined. For recipients with ILD, size-matching decisions are complicated by concerns regarding the potential impact of pre-LTx pulmonary restriction. We evaluate whether a specific donor-to-recipient size-matching strategy, based on predicted total lung capacity, benefits this patient group. This retrospective, single-centre, cohort study describes the post-LTx outcomes of adults who underwent LTx for ILD between 1983 and 2020. Only patients with restrictive physiology, based on pre-LTx pulmonary function testing were included. Post-LTx outcomes were compared based on donor-recipient predicted TLC (D-R pTLC) ratio. A D-R pTLC ratio of ≥0.8 or <1.2 for DLTx, and a D-R pTLC ratio of ≥0.8 or <1.0 for SLTx were classified as 'size-matched'. Five-hundred and fifty LTx recipients met inclusion criteria. Of these, 404 underwent DLTx and 146 underwent SLTx. Size-matching was achieved in 78% of DLTx and 47% of SLTx. Overall survival (p = 0.007) and CLAD-free survival (p < 0.001) was significantly improved following a size-matched DLTx, compared to those with D-R pTLC ratios <0.8 or ≥1.2. Size-matching based on a D-R pTLC ratio 0.8≥ <1.0 for SLTX did not significantly improve survival. D-R pTLC size-matching, based on a ratio of 0.8≥ <1.2 improved post-DLTx outcomes for patients with restrictive lung disease. This is simple to do, and if applied clinically, could improve overall outcomes in lung transplantation.

Sections du résumé

BACKGROUND
Donor-recipient size-matching has been repeatedly reported to improve outcomes following lung transplantation (LTx). However, there is significant variability in practice and the optimal strategy for size-matching is yet to be defined. For recipients with ILD, size-matching decisions are complicated by concerns regarding the potential impact of pre-LTx pulmonary restriction. We evaluate whether a specific donor-to-recipient size-matching strategy, based on predicted total lung capacity, benefits this patient group.
METHODS
This retrospective, single-centre, cohort study describes the post-LTx outcomes of adults who underwent LTx for ILD between 1983 and 2020. Only patients with restrictive physiology, based on pre-LTx pulmonary function testing were included. Post-LTx outcomes were compared based on donor-recipient predicted TLC (D-R pTLC) ratio. A D-R pTLC ratio of ≥0.8 or <1.2 for DLTx, and a D-R pTLC ratio of ≥0.8 or <1.0 for SLTx were classified as 'size-matched'.
RESULTS
Five-hundred and fifty LTx recipients met inclusion criteria. Of these, 404 underwent DLTx and 146 underwent SLTx. Size-matching was achieved in 78% of DLTx and 47% of SLTx. Overall survival (p = 0.007) and CLAD-free survival (p < 0.001) was significantly improved following a size-matched DLTx, compared to those with D-R pTLC ratios <0.8 or ≥1.2. Size-matching based on a D-R pTLC ratio 0.8≥ <1.0 for SLTX did not significantly improve survival.
CONCLUSIONS
D-R pTLC size-matching, based on a ratio of 0.8≥ <1.2 improved post-DLTx outcomes for patients with restrictive lung disease. This is simple to do, and if applied clinically, could improve overall outcomes in lung transplantation.

Identifiants

pubmed: 34301464
pii: S1053-2498(21)02388-3
doi: 10.1016/j.healun.2021.06.013
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1422-1430

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Auteurs

Peter Riddell (P)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Jin Ma (J)

Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, Canada.

Ben Dunne (B)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Matthew Binnie (M)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Marcello Cypel (M)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Laura Donahoe (L)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Marc de Perrot (M)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Andrew Pierre (A)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Tom K Waddell (TK)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Jonathan Yeung (J)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Kazuhiro Yasufuku (K)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

George Tomlinson (G)

Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, Canada.

Lianne G Singer (LG)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada.

Shaf Keshavjee (S)

Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Canada. Electronic address: shaf.keshavjee@uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH